Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Feb. 7, 2025 — Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to ... Personalized Cancer ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Cancer of the tonsil is a rare type of head and neck cancer. Cancer happens when abnormal cells start to divide and grow in an uncontrolled way. Symptoms often include a painless neck lump and a sore ...